Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer

Clinical trial NCT05863260 · UNKNOWN

Trial details

NCT number: NCT05863260
Sponsor: Fudan University
Status: UNKNOWN
Study type: OBSERVATIONAL

Cervical Cancer Immune Checkpoint Inhibitor Chemoradiotherapy

Start date: 2020-11-09
Primary completion: 2023-12-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.